Upsher-Smith Enhances Website for Qudexy XR Migraine Prevention Medicine
22 August 2017 - - US-based Upsher-Smith Laboratories, LLC has launched its enhanced website for Qudexy XR (topiramate) Extended-Release Capsules, the company said.
The site features the company's access pathways program designed to reduce the barriers associated with prescribing Qudexy XR, and offers healthcare professionals the tools necessary to help their patients start, stay, and save on Qudexy XR therapy, including an informational video, a guide on how to get started and a patient enrollment form.
Qudexy XR (topiramate) Extended-Release Capsules is a prescription medicine used to prevent migraine headaches in adults and adolescents 12 years and older, as an initial monotherapy to treat partial-onset seizures and primary generalised tonic-clonic seizures in adults and children two years and older, and as adjunctive therapy to treat certain types of seizures.
Upsher-Smith is a pharmaceutical company that provide a consistent supply of quality, affordable generic medications.
In June 2017, Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the US market.